Entrada Therapeutics, Inc. (TRDA)
- Previous Close
9.13 - Open
9.17 - Bid 6.48 x 200
- Ask 11.44 x 200
- Day's Range
8.83 - 9.46 - 52 Week Range
7.10 - 21.79 - Volume
51,627 - Avg. Volume
135,257 - Market Cap (intraday)
343.668M - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
5.39 - EPS (TTM)
1.68 - Earnings Date May 7, 2025 - May 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.33
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
www.entradatx.comRecent News: TRDA
View More
Performance Overview: TRDA
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRDA
View MoreValuation Measures
Market Cap
346.51M
Enterprise Value
-14.28M
Trailing P/E
5.43
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.69
Price/Book (mrq)
0.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
31.13%
Return on Assets (ttm)
5.90%
Return on Equity (ttm)
19.56%
Revenue (ttm)
210.78M
Net Income Avi to Common (ttm)
65.63M
Diluted EPS (ttm)
1.68
Balance Sheet and Cash Flow
Total Cash (mrq)
420M
Total Debt/Equity (mrq)
13.81%
Levered Free Cash Flow (ttm)
-73.29M
Research Analysis: TRDA
View MoreResearch Reports: TRDA
View MoreDaily – Vickers Top Buyers & Sellers for 05/17/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/27/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/22/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.